Pharming Group has nominated Fabrice Chouraqui as the successor to CEO Sijmen de Vries. His appointment will be subject to approval at an Extraordinary General Meeting of Shareholders (EGM).
Upon his appointment, Chouraqui will join the Board of Directors, while De Vries will step down as CEO. To ensure a smooth transition, De Vries will remain as a strategic advisor until December 31, 2025.
Richard Peters, Chairman of the Board of Directors, highlighted the expertise Chouraqui brings to Pharming:
“Fabrice is a highly experienced leader in the international pharmaceutical and biotechnology sectors. He brings extensive global expertise across the entire biopharmaceutical value chain, which will support Pharming in its next phase of growth.”
Chouraqui has held senior leadership roles at Novartis and Bristol-Myers Squibb, bringing a wealth of industry knowledge to Pharming.
With this appointment, Pharming reinforces its commitment to continuity and international expansion in the biotech sector.
To help address the growing need for well-trained production personnel in the Life Sciences industry, Talentmark and Biotech Training Facility (BTF) are joining forces to...
From 6–9 May 2025, the Netherlands Embassy in Seoul, in collaboration with the Netherlands Enterprise Agency (RVO), is organising a trade mission to South Korea focused on the...
Secure Your Spot in the Dutch Innovator Village at HLTH Europe 2025! Are you ready to present your health tech innovation to the world at HLTH Europe in RAI Amsterdam? Spaces are...